Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 38, Issue 12, Pages 1061-1084Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2017.09.002
Keywords
-
Categories
Funding
- Pediatric Cancer Research Group of the University of Nebraska Medical Center and Children's Hospital Omaha, Nebraska [LB805]
- Team Jack Foundation
Ask authors/readers for more resources
Medulloblastoma (MB) is the most common childhood brain tumor, which occurs in the posterior fossa. MB tumors are highly heterogeneous and have diverse genetic make-ups, with differential microRNA (miRNA) expression profiles and variable prognoses. MB can be classified into four subgroups, each with different origins, pathogenesis, and potential therapeutic targets. miRNA and small-molecule targeted therapies have emerged as a potential new therapeutic paradigm in MB treatment. However, the development of chemoresistance due to surviving cancer stem cells and dysregulation of miRNAs remains a challenge. Combination therapies using multiple drugs and miRNAs could be effective approaches. In this review we discuss various MB subtypes, barriers, and novel therapeutic options which may be less toxic than current standard treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available